A Phase 3 interventional study of Tobevibart and Elebsiran in Viral Hepatitis, sponsored by Vir Biotechnology, Inc.. Active, not recruiting at 39 sites in 10 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Vir Biotechnology, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in Hepatitis with a site in United States — 13 open to participants now, 17 under way, 2 of them phase 3. Hepatitis · United States.
Among the 144 studies in Hepatitis with a site in United States, this one is the 45th largest by enrollment of the 117 interventional ones that give a count, is one of 4 that started in 2025, is one of 22 in phase 3, reaches primary completion later than 4 of the 16 other live ones, and was the 136th registered.
344 studies on the registry are indexed under Hepatitis; 52 are open to participants now.
Browse Hepatitis studies →13 of the 144 studies in Hepatitis with a site in United States are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in United States, Canada, France and 3 more countries
Ages 18–65
Fox Chase Cancer Center · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Bausch Health Americas, Inc. · Sites in United States
Ages 18+
Samer Gawrieh · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 50 · Phase 3 25 · Phase 4 8
First in 1981; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 85 across 245 interventional studies indexed under Hepatitis.
Median enrollment 67 across the 117 interventional studies, 350 across the 26 observational. Of the 119 that completed or were terminated, 56 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 144 have an industry lead sponsor. The 10 most frequent:
Vir Biotechnology, Inc. is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.
Vir Biotechnology, Inc. has 9 studies filed under Hepatitis — fewer than ten, so there is no comparison to draw.
5 of the studies in Hepatitis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07428538Phase 3Bausch Health Americas, Inc.Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | 2027-11 |
| NCT07654283AusperBio Therapeutics Inc.Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions | 2027-05-11 |
| NCT07122700Foundation for the National Institutes of HealthEvaluation of Non-Invasive Tests for Metabolic Liver Disease | 2027-06-30 |
| NCT06266416University of Illinois at ChicagoIMARA for Black Male Caregivers and Girls Empowerment (IMAGE) | 2027-07-30 |
| NCT06836609Regeneron PharmaceuticalsA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) | 2027-08-17 |
Add all 5 to your calendar (.ics) → With an account.
Among the 144 studies in Hepatitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive treatment with tobevibart + elebsiran for 240 weeks.
Drug: Tobevibart · Drug: Elebsiran
Participants will receive tobevibart + elebsiran after an observational period for 240 weeks.
Drug: Tobevibart · Drug: Elebsiran
Tobevibart administered by subcutaneous injection
Also known as: VIR-3434
Elebsiran administered by subcutaneous injection
Also known as: VIR-2218
HDV RNA < Lower Limit of Quantification (LLOQ), Target Not Detected (TND) and alanine aminotransferase (ALT) normalization (ALT </= Upper Limit of Normal [ULN]) at Week 48 for Arm 1 vs at Week 12 for Arm 2
Time frame: Up to 48 weeks
Incidence of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 12
Time frame: Up to 12 weeks
HDV RNA < LLOQ, TND at Week 48 for Arm 1 vs Week 12 for Arm 2
Time frame: Up to 48 weeks
Ran from Mar 2025 to primary completion in Sep 2026, 18 months.
Of 23 phase 3 interventional studies under Hepatitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 18 months is below that.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Sep 2026, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tobevibart · Elebsiran